Neurogene, Inc. Common Stock (NGNE)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 131
- Market Cap
- $670M
About Neurogene, Inc. Common Stock
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
SentiSense also tracks daily options readings for Neurogene, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Neurogene, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.